KPV
KPV is the three-amino-acid C-terminal fragment of alpha-melanocyte-stimulating hormone (α-MSH). It has drawn attention for anti-inflammatory effects in cell and animal models, especially in gut-inflammation research. More recently, preclinical work has expanded into adipogenesis and metabolic biology. The scientific signal is real. The human treatment story is not yet established.
Human efficacy unproven.
FDA reported in 2026 that it could not identify clinical studies of KPV use in humans for wound healing or inflammatory conditions.
Three amino acids.
A much bigger story.
KPV stands for lysine-proline-valine—the C-terminal tripeptide fragment of α-MSH.
Unlike full-length melanocortin peptides, KPV appears to retain anti-inflammatory activity without behaving simply as a classic melanocortin-receptor agonist. Early work suggested that some of its anti-inflammatory effects may be independent of melanocortin receptor signaling and may involve modulation of inflammatory cytokine activity.
This is where the story gets thin.
Most of the KPV literature is preclinical. Research has explored KPV in cell systems and animal models of colitis, peritonitis, wound-related inflammation and, more recently, adipogenesis and diet-induced metabolic dysfunction.
What is missing is the key bridge: controlled human therapeutic evidence. In its 2026 review of KPV-related bulk drug substances for possible 503A Bulks List inclusion, FDA said it did not identify clinical studies of KPV in humans for the nominated uses of wound healing and inflammatory conditions.
The anti-inflammatory label travels farther than the data.
KPV may be the clearest example of community momentum outrunning clinical evidence.
Rising interest
Online discussion increasingly centers on gut inflammation, systemic inflammation, skin-related inflammation and pairing KPV with other recovery peptides.
- Frequently framed as a “gut peptide”
- Often discussed alongside BPC-157 and TB-500
- Growing interest in broader anti-inflammatory effects
- Community use patterns greatly exceed the clinical evidence base
Essentially absent
The human therapeutic evidence base is extremely limited. FDA’s 2026 review said it did not identify clinical studies of KPV in humans for the nominated inflammatory and wound-healing uses.
- No established human efficacy trials
- No FDA-approved KPV drug product
- Human exposure data are not established in FDA’s review
- Most positive evidence comes from cells and animals
KPV has become a recognizable name in peptide communities despite lacking the kind of human therapeutic evidence that would normally support confident claims about efficacy, safety or ideal use.
Small peptide. Large unknowns.
KPV has no FDA-approved therapeutic use, and its human safety profile is not well characterized.
FDA’s current compounding safety-risk page states that the agency has not identified human exposure data on drug products containing KPV administered by any route and lacks important information about potential safety issues, including whether KPV would cause harm if administered to humans.
KPV is moving from niche peptide to regulatory scrutiny.
Research
New preclinical research pushed KPV into metabolic territory.
A 2026 study reported that KPV suppressed adipocyte differentiation in 3T3-L1 cells and mitigated obesity-related metabolic changes in a high-fat-diet mouse model. It broadens the research story—but remains preclinical.
Regulatory
FDA formally reviewed KPV-related bulk drug substances.
KPV free base and acetate were considered in the 503A Bulks List process for wound healing and inflammatory conditions. FDA’s review found no human clinical evidence for the nominated uses and highlighted the lack of human safety data.
Research
Gut-inflammation models built KPV’s modern reputation.
Mouse colitis studies reported anti-inflammatory effects, and later targeted nanoparticle delivery work showed that KPV could reduce colitis-related inflammatory measures in animal models.
Show the receipts.
| Evidence | Design | What it adds | What it cannot prove |
|---|---|---|---|
| Anti-inflammatory mechanism · PMID 12750433 | Cell + mouse inflammation models | Shows anti-inflammatory activity distinct from classic melanocortin receptor signaling. | Does not establish human efficacy or safety. |
| Murine colitis · PMID 18092346 | Two mouse models of intestinal inflammation | Demonstrated reduced inflammatory changes and improved recovery in animal colitis models. | Does not establish KPV as a human IBD therapy. |
| Targeted colon delivery · PMID 19909746 | Cell + mouse colitis model | Supports localized delivery of KPV and anti-inflammatory activity in preclinical intestinal disease. | Does not establish oral KPV efficacy in humans. |
| Adipogenesis / obesity · PMID 42585803 | Cell + mouse metabolic study | Expands KPV’s preclinical research into adipogenesis and obesity-related metabolism. | Does not establish human fat-loss or metabolic efficacy. |
| FDA 2026 compounding review | Regulatory evidence review | Documents lack of human clinical evidence for nominated uses and lack of human exposure/safety data. | Does not determine what future pharmaceutical development might eventually show. |
Read deeper.
Follow the evidence.
Gut Health
Explore the biology of intestinal inflammation and the compounds most often discussed around gut-focused optimization.
TB-500
See another high-interest recovery peptide where community reputation substantially exceeds molecule-specific human evidence.
MOTS-c
See another case where compelling biology and community interest run ahead of therapeutic human evidence.
SS-31 / Elamipretide
See what a much deeper human clinical-development program and an FDA-approved indication look like.